An investigational once-weekly oral antiretroviral therapy (ART) combination effectively maintained viral suppression in ...

The US Food and Drug Administration (FDA) has accepted MSD’s doravirine/islatravir (DOR/ISL) new drug application (NDA) for ...

Rahway, New Jersey Wednesday, July 16, 2025, 17:30 Hrs [IST] ...

In addition, a new class of antiretrovirals inhibiting integrase enzymes (integrase inhibitors) have shown very promising results in adults, but have not been studied yet in children.

Dual Inhibitor: A compound designed to concurrently inhibit two distinct enzymatic activities, such as the polymerase and RNase H functions of reverse transcriptase or both RT and integrase.

TPN-101, a potent nucleoside reverse transcriptase inhibitor that specifically inhibits the LINE-1 reverse transcriptase.

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

Use of nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs) is associated with an increased risk for primary ...

Merck MRK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval for its ...

If approved, doravirine/islatravir would be the first two-drug HIV treatment regimen without an integrase inhibitor, ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the EXPrESSIVE Phase 3 clinical trials, evaluating the safety and efficacy of MK-8527, an ...